INVESTOR ALERT: Investigation of Trinity Biotech plc Announced by Law Offices of Howard G. Smith
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Trinity Biotech plc
(“Trinity” or the “Company”) (NASDAQ: TRIB) concerning the Company and its officers’ possible violations of federal securities laws.
Trinity acquires, develops, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care
(POC) segments of the diagnostic market.
The investigation concerns Trinity’s October 4, 2016 announcement that the Company was withdrawing its 510(k) premarket
notification submission for the Meritas Troponin-I Test and Meritas Point-of-Care Analyzer on the recommendation of the U.S. Food
and Drug Administration. On news of the withdrawal, Trinity’s share price fell over 50% to close at just $6.46 per share on October
4, 2016, thereby injuring investors.
If you purchased Trinity securities, have information or would like to learn more about these claims, or have any questions
concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of
Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847,
toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161006006491/en/